Article info

Download PDFPDF
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
  1. Correspondence to:
    Dr Magnus Janzon, Department of Cardiology, Linköping Heart Centre, University Hospital, SE-581 85 Linköping, Sweden;
    magnus.janzon{at}imv.liu.se
View Full Text

Citation

Janzon M, Levin L, Swahn E
Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial

Publication history

  • Accepted October 2, 2002
  • First published March 1, 2003.
Online issue publication 
March 01, 2003

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.